Muscle Mass
Conditions
Keywords
Weight loss, GLP-1 agonist, Obesity, Lean mass, Body composition, Strength training
Brief summary
GLP-1 medication is being prescribed for weight loss. However, GLP-1 medication may adversely affect muscle mass and muscle function. Moreover, any loss of muscle mass or muscle function with GLP-1 treatment may impair balance and increase fall risk. This is a particular concern among older adults already susceptible to the common muscle strength and muscle function loss with age, yet there is little evidence among this population. This study will address a gap in knowledge regarding the effects of GLP-1 treatment on muscle mass, muscle function, and balance/fall risk among adults age 50 and older.
Interventions
BEHAVIORALStrength Training
Participants taking a GLP-1 will undergo a 14-week strength training regimen to determine changes in muscle mass. They will perform a series of resistance training exercises supervised by a personal trainer on 3 days per week.
OTHERWait first, then strength training
Participants will be waitlisted and receive the 14-week strength training intervention at the end of the waitlist period. During the waitlist period, participants will get no intervention and then be offered the strength training intervention after the first 14 weeks.
Sponsors
Virginia Polytechnic Institute and State University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age, 50y+ * Be taking GLP-1 medicine (Weygovy or Zepbound) for 1 month or less * Weight \<300 lb * Pass a health and exercise readiness screening
Exclusion criteria
* Age \<50 * Weight \>300 lb * Osteoporosis * Active metabolic, neoplastic, or cardiovascular disease * Unable or unwilling to provide consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Muscle mass by d3-creatine dilution | Water containing creatine isotope consumed in lab; Urine sample collection on Day 0 and Day 3 at baseline and 14 weeks. | Participants will collect a urine sample prior to be provided a creatine capsule containing 30 milligrams of a naturally-occurring creatine isotope. A glass of water will be provided to wash it down. Participants will be asked to return \~3 days later to provide another urine sample. Urine samples will be analyzed at an off-site laboratory to determine changes in d3-creatine excretion before and after the 14-week strength training intervention. |
| Balance testing - Percentage of failed recoveries | 2-hour testing session in lab at baseline and 14 weeks. | Participants will stand on the treadmill with the belt stationary. The belt will then suddenly change to a speed specified by the investigator, and the participant will attempt to step to maintain their balance and establish a stable gait. In addition to the treadmill itself, this system includes an integrated fall arrest harness that is anchored to an overhead gantry that is fixed to the treadmill. This harness prevents any body part but the feet from impacting the treadmill in the event that the participant is unable to maintain their balance after a sudden change in speed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Muscle function | 500-meter timed walk in lab at baseline and 14 weeks | Participants will walk 500 meters down and back along a hallway at a self-selected pace. The walk will be measured, supervised, and timed by lab personnel. |
Countries
United States
Contacts
CONTACTKevin Davy
CONTACTElaina Marinik
PRINCIPAL_INVESTIGATORKevin Davy
Virginia Polytechnic Institute and State University
Outcome results
None listed